Open-label, Pilot Protocol of Patients With Rheumatoid Arthritis Who Switch to Infliximab After Incomplete Response to Etanercept.

Trial Profile

Open-label, Pilot Protocol of Patients With Rheumatoid Arthritis Who Switch to Infliximab After Incomplete Response to Etanercept.

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Apr 2010

At a glance

  • Drugs Etanercept; Infliximab
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms OPPOSITE
  • Sponsors Janssen Biotech
  • Most Recent Events

    • 13 Apr 2010 Actual number of patients (20) added as reported by ClinicalTrials.gov record.
    • 13 Apr 2010 Actual number of patients (20) added as reported by ClinicalTrials.gov record.
    • 01 Jul 2007 Results have been published.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top